First in Human Trial of TAS266 in Patients With Advanced Solid Tumors

NCT01529307 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: TAS266

Sponsor

Novartis Pharmaceuticals